title: Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
abstract: The effects on linear growth and development among thalassemic patients under different treatment regimens were compared. Twelve homozygous beta-thalassemia (homozygous beta-thal) and 36 beta-thalassemia/Hb E (beta-thal/Hb E) were studied longitudinally between 1977 and 1998. Eighteen cases (10 homozygous beta-thal and 8 beta-thal/Hb E) received hypertransfusion with iron chelation by desferrioxamine. Another 30 cases (2 homozygous beta-thal and 28 beta-thal/Hb E) were given a low transfusion (depending on their clinical requirement). Their heights were measured serially and are presented as a standard deviation score (SDS). There was no significant difference in initial basic hematological data and ferritin levels between either group. However, the hypertransfused group, seemed to be clinically more severely affected than the other group as evidenced by early age at initial transfusion, the early onset of anemia and diagnosis and also their large acquired iron load after a period of transfusion. The average height SDS of the hypertransfused patients was within the 50th percentile +/- 1 SD during the first decade of life in both sexes and both genotypes. Whereas, in patients who were transfused infrequently, the SDS was always below the -1 SD and decreased gradually. In severe beta-thal/Hb E cases, their growth SDS showed no difference from those with homozygous beta-thal. Normal linear growth in those with homozygous beta thal and severe beta-thal/Hb E was only seen in the group that underwent hypertransfusion and this regimen contributed to normal growth during the first ten years of life. However, adequate iron chelation and hormonal treatment in these patients were also required in order to achieve normal adult height.
authors.affiliation: Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: V
authors.initials: V
authors.lastname: Viprakasit
authors.forename: V S
authors.initials: VS
authors.lastname: Tanphaichitr
authors.forename: C
authors.initials: C
authors.lastname: Mahasandana
authors.forename: A
authors.initials: A
authors.lastname: Assteerawatt
authors.forename: L
authors.initials: L
authors.lastname: Suwantol
authors.forename: G
authors.initials: G
authors.lastname: Veerakul
authors.forename: S
authors.initials: S
authors.lastname: Kankirawatana
authors.forename: P
authors.initials: P
authors.lastname: Pung-Amritt
authors.forename: V
authors.initials: V
authors.lastname: Suvatte
mesh_terms: D001803:Blood Transfusion; D001827:Body Height; D001835:Body Weight; D016009:Chi-Square Distribution; D002648:Child; D003676:Deferoxamine / Q000627:therapeutic use; D005260:Female; D006130:Growth Disorders / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D016014:Linear Models; D008137:Longitudinal Studies; D008297:Male; D011627:Puberty / Q000502:physiology; D018709:Statistics, Nonparametric; D017086:beta-Thalassemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D007502:Iron Chelating Agents; D003676:Deferoxamine